News und Analysen
![Premier, Inc. Reports Fiscal 2020 Fourth-Quarter and Full-Year Results](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Premier, Inc. Reports Fiscal 2020 Fourth-Quarter and Full-Year Results
Premier, Inc. (NASDAQ: PINC) today reported financial results for the fiscal year (FY) 2020 fourth quarter and full year ended June 30, 2020.
All results presented in this press release reflect
![Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting
Ipsen (Euronext: IPN; ADR: IPSEY) today announced results from the MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP), to be presented during
![Antibe Therapeutics Reports Q1 2021 Interim Financial and Operating Results](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Antibe Therapeutics Reports Q1 2021 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Monday, August 24 for the fiscal quarter ended June 30, 2020. The
![Navidea Biopharmaceuticals to Present at The LD 500 Virtual Investor Conference](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Navidea Biopharmaceuticals to Present at The LD 500 Virtual Investor Conference
Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced
![QIAGEN führt einfach zu bedienenden, digitalen Test zum Nachweis von SARS-CoV-2-Antikörpern nach beantragter FDA-Notfallzulassung auf dem US-Markt ein](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
QIAGEN führt einfach zu bedienenden, digitalen Test zum Nachweis von SARS-CoV-2-Antikörpern nach beantragter FDA-Notfallzulassung auf dem US-Markt ein
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Einführung seines neuen Access Anti-SARS-CoV-2 Total Tests auf dem US-Markt bekannt. Hierbei handelt es sich um einen einfach
![QIAGEN to Launch Easy-to-Use Digital Test in the U.S. for Rapid Detection of SARS-CoV-2 Antibodies Following FDA Emergency Use Authorization](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
QIAGEN to Launch Easy-to-Use Digital Test in the U.S. for Rapid Detection of SARS-CoV-2 Antibodies Following FDA Emergency Use Authorization
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of the new Access Anti-SARS-CoV-2 Total test, an easy-to-use digital test done on a portable device that
![QIAGEN announces new Chairman of Supervisory Board](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
QIAGEN announces new Chairman of Supervisory Board
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced today a transition in the leadership of its Supervisory Board after an extraordinary meeting of the Supervisory Board and
![QIAGEN gibt neuen Aufsichtsratsvorsitzenden bekannt](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
QIAGEN gibt neuen Aufsichtsratsvorsitzenden bekannt
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute im Anschluss an eine außerordentliche Sitzung des Aufsichtsrats und des Vorstands einen Wechsel im Vorsitz des Aufsichtsrats
![Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vaccine program against
![Antibe Therapeutics Announces Results of Annual and Special Meeting](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Antibe Therapeutics Announces Results of Annual and Special Meeting
Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual and special meeting held earlier today. All resolutions outlined in the management information
![Quidel Concludes Sofia® SARS Antigen Investigation From Vermont](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Quidel Concludes Sofia® SARS Antigen Investigation From Vermont
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![EnWave to Report Third Quarter Fiscal 2020 Financial Results on August 27, 2020 and Provides NutraDried Update](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
EnWave to Report Third Quarter Fiscal 2020 Financial Results on August 27, 2020 and Provides NutraDried Update
Vancouver, B.C., August 20th, 2020 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), a global
![EnWave berichtet das dritte Quartal des Geschäftsjahres 2020 am 27. August 2020 und gibt Update zu NutraDried](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
EnWave berichtet das dritte Quartal des Geschäftsjahres 2020 am 27. August 2020 und gibt Update zu NutraDried
Vancouver, B.C., 20. August 2020 - Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), ein
![Quidel to Update Packaging of Point-of-Care Sofia® SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Quidel to Update Packaging of Point-of-Care Sofia® SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that labeling for
![Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the publication of interim results from its Phase II CONTROL trial of neratinib in the September 2020 Issue (Volume
![Momenta Pharmaceuticals: Nächste Mega-Übernahme im US-Biotechsektor!](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Momenta Pharmaceuticals: Nächste Mega-Übernahme im US-Biotechsektor!
Zuletzt verging kaum ein Tag, an dem nicht irgendeine Mega-Übernahme im US-Biotechsektor vermeldet wurde. So auch heute. Denn heute verkündete Johnson & Johnson die Übernahme von Momenta
![True Leaf schließt Vereinbarung über den Verkauf von True Leaf Pet Inc. ab](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
True Leaf schließt Vereinbarung über den Verkauf von True Leaf Pet Inc. ab
Vernon (British Columbia), 19. August 2020. True Leaf Brands Inc. (CSE: MJ) (OTCQX: TRLFF) (FWB: TLA) („True Leaf“) gibt heute bekannt, dass True Leaf Pet Inc. („TLP“) im Rahmen des
![True Leaf Enters into Asset Purchase Agreement to Sell True Leaf Pet Inc.](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
True Leaf Enters into Asset Purchase Agreement to Sell True Leaf Pet Inc.
Vernon, BC - August 19, 2020 - True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FSE: TLA) (“True Leaf”) announced today that, as part of the sales process approved by Order of the British
![Relay Medical and Fio Corporation Announce Joint Venture for Pandemic Testing Technology](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Relay Medical and Fio Corporation Announce Joint Venture for Pandemic Testing Technology
August 19, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”) are pleased to announce the establishment of a joint
![Relay Medical und Fio Corporation gründen Joint Venture für Pandemie-Testmethode](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Relay Medical und Fio Corporation gründen Joint Venture für Pandemie-Testmethode
19. August 2018 – Relay Medical Corp. („Relay“ oder das „Unternehmen“) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) und Fio Corporation („Fio“) freuen sich, die Gründung eines Joint Ventures („J
![Agilent Reports Third-Quarter Fiscal Year 2020 Financial Results](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Agilent Reports Third-Quarter Fiscal Year 2020 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.26 billion for the third quarter ended July 31, 2020, a decline of 1% compared to the third quarter of 2019 and down 3.1% on a core(
![QIAGEN bestärkt COVID-19-Forschung mit integrierten Coronavirus-NGS- und Software-Lösungen](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
QIAGEN bestärkt COVID-19-Forschung mit integrierten Coronavirus-NGS- und Software-Lösungen
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat das innovative QIAseq-SARS-CoV-2-Primer-Panel für Next-Generation-Sequencing (NGS) des Genoms des neuartigen Coronavirus sowie integrierte
![QIAGEN Expands Integrated Coronavirus NGS and Software Solutions to Accelerate COVID-19 Research](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
QIAGEN Expands Integrated Coronavirus NGS and Software Solutions to Accelerate COVID-19 Research
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) launched the innovative QIAseq SARS-CoV-2 Primer Panel for next-generation sequencing (NGS) of the novel coronavirus genome, along with integrated
![Premier Inc. Working with AstraZeneca to Reduce Hospitalizations of Patients with Hyperkalemia](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Premier Inc. Working with AstraZeneca to Reduce Hospitalizations of Patients with Hyperkalemia
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today it has reached a significant milestone in its partnership with AstraZeneca, a global, science-led